Strategic Partnerships There is potential to expand collaborations with healthcare tech integrators and AI healthcare platforms, given Breathomix's BreathBase solution and existing Evalan partnership. Target partners that can help scale deployment, data integration, and multi-centre studies to accelerate market adoption.

Clinical Validation Breathomix has already pursued multi-centre prospective clinical studies related to respiratory infections, including Covid-19. Leverage funded or continuing clinical validation opportunities to position BreathBase as a benchmark non-invasive diagnostic alongside traditional tests.

Healthcare Adoption With a tight team and focus on non-invasive, rapid breath analysis, there is an opportunity to sell to clinics, hospitals, and specialty centers seeking faster triage and precision medicine tools, especially in chronic respiratory, cancer, and infectious disease pathways.

Data & AI Engine The AI-powered platform and growing reference database are key differentiators. Sales motions can highlight real-time analysis, on-site capability, and data-driven outcomes to hospital procurement and research organizations looking for advanced diagnostic analytics.

Low-Volume Startup Growth Revenue is under $1M with a small employee base, suggesting an emphasis on scalable pilots and strategic, high-value contracts rather than broad commodity sales. Prioritize pilot programs, clarity on ROI, and phased deployments to win key customers.